Symptom profiles and vaccination status for COVID‐19 after the adjustment of the dynamic zero‐COVID policy in China: An observational study

Zhang, H.; Lu, Zhenyu; Fan, Yang; Chen, Hongwei; Zhang, Le; Zhao, Huiying; Chen, Yongkun

doi:10.1002/jmv.28893

Cited by 3 publications

(1 citation statement)

References 23 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diversity of lineages varied among provinces and cities, suggesting regional differences in pandemic patterns. This variation in transmission advantage between BA.5.2 and BF.7 lineages is supported by different regions exhibiting distinct symptom profiles (27)(28)(29). Prior to December 2022, sporadic occurrence of BA.5.2 and its descendant lineages as well as BF.7 and its descendant lineages, was observed in China (30).…”

Section: Discussionmentioning

confidence: 93%

Genomic evolution of BA.5.2 and BF.7.14 derived lineages causing SARS-CoV-2 outbreak at the end of 2022 in China

Zhu,

Wang,

Lin

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

Since the end of 2022, when China adjusted its COVID-19 response measures, the SARS-CoV-2 epidemic has rapidly grown in the country. It is very necessary to monitor the evolutionary dynamic of epidemic variants. However, detailed reports presenting viral genome characteristics in China during this period are limited. In this study, we examined the epidemiological, genomic, and evolutionary characteristics of the SARS-CoV-2 genomes from China. We analyzed nearly 20,000 genomes belonging to 17 lineages, predominantly including BF.7.14 (22.3%), DY.2 (17.3%), DY.4 (15.5%), and BA.5.2.48 (11.9%). The Rt value increased rapidly after mid-November 2022, reaching its peak at the end of the month. We identified forty-three core mutations in the S gene and forty-seven core mutations in the ORF1ab gene. The positive selection of all circulating lineages was primarily due to non-synonymous substitutions in the S1 region. These findings provide insights into the genomic characteristics of SARS-CoV-2 genomes in China following the relaxation of the ‘dynamic zero-COVID’ policy and emphasize the importance of ongoing genomic monitoring.

show abstract

Section: Discussionmentioning

confidence: 93%

Genomic evolution of BA.5.2 and BF.7.14 derived lineages causing SARS-CoV-2 outbreak at the end of 2022 in China

Zhu,

Wang,

Lin

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

Coronavirus disease 2019 and psoriatic arthritis: Features and connections

Yao,

Liang,

et al. 2024

Rheumatology & Autoimmunity

View full text Add to dashboard Cite

BackgroundLittle is known about the characteristics of patients with psoriatic arthritis (PsA) during the coronavirus disease 2019 (COVID‐19) pandemic. This study aimed to evaluate the impact of COVID‐19 on PsA progression and comprehend the role of COVID‐19 vaccination in the infection course.MethodsA total of 163 adult patients with PsA from 15 provinces in China were enrolled in this multiregional observational study from January 14, 2023, to March 22, 2023. Data on patient demographics, COVID‐19 status, and disease characteristics were collected through a structured questionnaire survey.ResultsSevere acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections could worsen PsA, with 29.0% of patients experiencing deteriorating symptoms. Psoriasis was the symptom most exacerbated (61.1%), followed by peripheral arthritis (52.8%) and dactylitis (25.0%). Compared with the patients whose arthritic condition was stable before contracting COVID‐19, those with active PsA experienced more severe COVID‐19 symptoms, reporting higher self‐assessed symptom severity scores and a greater prevalence of dyspnea (42.9% vs. 7.3%). Moreover, although full vaccination (≥2 doses) could not prevent COVID‐19, it could alleviate the infection symptoms, including diarrhea, fatigue, appetite changes, and spondyloarthritis. Additionally, fully vaccinated individuals had a higher probability of avoiding deterioration of their PsA condition after infection.ConclusionActive PsA and lack of COVID‐19 vaccination are risk factors for worsening COVID‐19 symptoms and PsA condition after infection. The evidence from this real‐world study suggests that COVID‐19 may exacerbate PsA.

show abstract

Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses

Meyerowitz,

2023

Clinical Infectious Diseases

View full text Add to dashboard Cite

The goals of COVID-19 antiviral therapy early in the pandemic were to prevent severe disease, hospitalization, and death. As these outcomes have become infrequent in the age of widespread population immunity, the objectives have shifted. For the general population, COVID-19-directed antiviral therapy should decrease symptom severity and duration and minimize infectiousness and for immunocompromised individuals, antiviral therapy should reduce severe outcomes and persistent infection. The increased recognition of virologic rebound following ritonavir-boosted nirmatrelvir (NMV/r) and the lack of randomized controlled trial data showing benefit of antiviral therapy for SARS-CoV-2 infection for standard-risk, vaccinated individuals remain major knowledge gaps. Here, we review data for selected antiviral agents and immunomodulators currently available or in late-stage clinical trials for use in outpatients. We do not review antibody products, convalescent plasma, systemic corticosteroids, IL-6 inhibitors, Janus kinase inhibitors, or agents which lack FDA approval or emergency use authorization or are not appropriate for outpatients.

show abstract

Symptom profiles and vaccination status for COVID‐19 after the adjustment of the dynamic zero‐COVID policy in China: An observational study

Cited by 3 publications

References 23 publications

Genomic evolution of BA.5.2 and BF.7.14 derived lineages causing SARS-CoV-2 outbreak at the end of 2022 in China

Genomic evolution of BA.5.2 and BF.7.14 derived lineages causing SARS-CoV-2 outbreak at the end of 2022 in China

Coronavirus disease 2019 and psoriatic arthritis: Features and connections

Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses

Contact Info

Product

Resources

About